| 598.72 5.18 (0.87%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 710.94  |
1-year : | 830.38 |
| Resists | First : | 608.69 |
Second : | 710.94 |
| Pivot price | 566.91 |
|||
| Supports | First : | 523.44 |
Second : | 470.76 |
| MAs | MA(5) : | 592.55 |
MA(20) : | 560.43 |
| MA(100) : | 530.39 |
MA(250) : | 521.8 |
|
| MACD | MACD : | 20.1 |
Signal : | 16.7 |
| %K %D | K(14,3) : | 90.1  |
D(3) : | 92.7 |
| RSI | RSI(14): 70.1 |
|||
| 52-week | High : | 609.34 | Low : | 430.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ UTHR ] has closed below upper band by 16.0%. Bollinger Bands are 97.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 609.26 - 611.6 | 611.6 - 614.29 |
| Low: | 587.2 - 589.71 | 589.71 - 592.6 |
| Close: | 594.05 - 598.08 | 598.08 - 602.71 |
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Thu, 29 Oct 2026
United Therapeutics Corporation (UTHR) Seasonal returns chart - Yahoo Finance UK
Thu, 29 Oct 2026
United Therapeutics Corporation (UTHR) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore
Thu, 29 Oct 2026
United Therapeutics Corporation (UTHR) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Thu, 29 Oct 2026
United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension Therapy - Yahoo! Finance Canada
Wed, 28 Oct 2026
United Therapeutics(UTHR.US) Officer Sells US$5.58 Million in Common Stock - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 100.1 (%) |
| Shares Short | 3,600 (K) |
| Shares Short P.Month | 2,060 (K) |
| EPS | 29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 149.97 |
| Profit Margin | 41.5 % |
| Operating Margin | 42.2 % |
| Return on Assets (ttm) | 11.6 % |
| Return on Equity (ttm) | 19.3 % |
| Qtrly Rev. Growth | -1.9 % |
| Gross Profit (p.s.) | 63.41 |
| Sales Per Share | 73.44 |
| EBITDA (p.s.) | 34.97 |
| Qtrly Earnings Growth | 13.3 % |
| Operating Cash Flow | 1,690 (M) |
| Levered Free Cash Flow | 557 (M) |
| PE Ratio | 20.64 |
| PEG Ratio | 2.2 |
| Price to Book value | 3.99 |
| Price to Sales | 8.15 |
| Price to Cash Flow | 15.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|